Navigation Links
REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
Date:6/1/2009

Boston, MA June 1, 2009 REGiMMUNE Corporation today announced that its lead product candidate RGI-2001, in combination with a low-dose of Sirolimus, demonstrated enhanced efficacy in transplantation tolerance induction in models of skin transplantation and acute Graft-versus-Host disease (GvHD). This data is being presented today in a poster titled "Donor-Specific Tolerance Induction by a Liposomal Formulation of KRN7000 (RGI-2001) Alone and in Combination with Low-Dose Sirolimus" at the 2009 American Transplant Congress being held in Boston.

"We are extremely pleased to present this data," stated Haru Morita, President and Chief Executive Officer of REGiMMUNE. "The study not only demonstrated the efficacy of RGI-2001 in solid organ transplants; it showed the potential of RGI-2001 to induce antigen-specific transplantation tolerance, which is considered a holy grail in transplantation."

KRN7000, a synthetic derivative of alpha-galactosylceramide, is a small molecule that potently activates natural killer T (NKT) cells. RGI-2001 is a proprietary liposomal formulation of KRN7000. RGI-2001 monotherapy has shown to induce antigen-specific immune suppression by inducing regulatory T cells (Tregs). Tregs are believed to play a central role in inducing and maintaining immune tolerance. The study was designed to evaluate the efficacy of RGI-2001 in combination with Sirolimus in transplantation tolerance induction in mouse models.

Study Results

Pharmacological induction of alloantigen-specific tolerance is expected to provide significant clinical benefits in organ transplantation and bone marrow transplantation. The REGiMMUNE study concluded that the addition of a subtherapeutic dose of Sirolimus enhanced the efficacy of RGI-2001 in both models. The combination treatment significantly prolonged the survival of grafts in the skin transplant model over Sirolimus single treatment. Likewise, GvHD mortality was reduced by the combination treatment. In addition, the combination of RGI-2001 with low-dose Sirolimus significantly enhanced Treg induction.

The results indicate the potential of RGI-2001 to be a key component of a novel tolerance induction regimen, avoiding the use of calcineurin inhibitors that are not only associated with high toxicity but suppress Treg activity. The finding suggests the possibility to develop a pharmacological approach to induce long-term transplant tolerance by promoting the body's intrinsic tolerogenic pathways using RGI-2001.

RGI-2001 is in late preclinical development and REGiMMUNE plans to file an Investigational New Drug (IND) for the prevention of acute GvHD associated with bone marrow transplantation later this year.

The poster presentation is scheduled during the session "Tolerance I: Regulatory Cells" today in Exhibit Hall C, Hynes Convention Center. It is available for viewing from 8:00 am to 6:30 pm; and the authors, Drs. Omar Duramad and Reiko Namikawa, will be present from 5:30 pm to 6:30 pm for discussion and questions.


'/>"/>

Contact: Debra Bannister
530-676-8001
REGiMMUNE
Source:Eurekalert

Related biology news :

1. REGiMMUNE receives $12 million in grants to develop transplant and allergy drugs
2. Biolex presents Locteron US Phase 2a hepatitis C data at EASL
3. GSA special paper presents new studies of Western US earth motion
4. AIUM Presents 2009 Joseph H. Holmes Pioneer Awards
5. AIUM presents 2009 Memorial Hall of Fame awards
6. AIUM presents 2009 Distinguished Sonographer award
7. AIUM presents 2009 William J. Fry Memorial Lecture award
8. Stevens Center for Science Writings presents: Ravens at the Feast, with Bernd Heinrich, April 1
9. Understanding soil carbon sequestration: New book presents key concepts
10. World Congress on Osteoporosis 2010 presents outstanding scientific program
11. New manual presents robust, state-of-the-art proteomics methods for teaching and research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2016)... SAN JOSE, Calif. , Jan. 18, 2016 ... storage security software that simplifies the use and ... a technology and go-to-market partnership with American Cyber.  ... "American Cyber brings extensive experience leading transformational C4ISR ... missions implementing and integrating the latest proven technology ...
(Date:1/13/2016)... 13, 2016 --> ... new market report titled - Biometric Sensors Market - Global ... - 2023. According to the report, the global biometric sensors market was ... to reach US$1,625.8 mn by 2023, expanding at a ... of volume, the biometric sensors market is expected to ...
(Date:1/11/2016)... 11, 2016 Synaptics Incorporated (NASDAQ: SYNA ... announced that its ClearPad ® TouchView ™ ... two separate categories in the 8 th Annual ... Technology Breakthrough. The Synaptics ® TDDI solution enables ... chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... ... February 09, 2016 , ... The publishing ... Open Access publishing is one of the popular publication models that has received ... journals and 3000+ International Conferences across the globe, OMICS International ...
(Date:2/9/2016)... , Feb. 9, 2016 This market research ... current and future prospects of the market in terms ... include companies engaged in the manufacture of microbiology culture ... summary with a market snapshot providing the overall information ... this report. This section also provides the overall information ...
(Date:2/9/2016)... Feb. 9, 2016 BERG, a biopharmaceutical ... research approach, has announced the appointment of ... Chief Operating Officer. Haddock brings to BERG over ... 12 years in senior financial functions at pharmaceutical ... business organizational management. Niven R. ...
(Date:2/8/2016)... PLYMOUTH MEETING, Pa. , Feb. 8, 2016 /PRNewswire-USNewswire/ ... place of standard bone cement products to prevent infection ... a question that the experts at ECRI Institute have ... Cement: Fighting Infection or Fighting Your Bottom Line?" ... or Fighting Your Bottom Line?" --> ...
Breaking Biology Technology: